Managed Care Review Board™ Presents: Health Plan Best Practice Insights to Improve Outcomes for Non-Small Cell Lung Cancer

Learn About:

The cost-effectiveness of various treatment options for NSCLC
Social determinants of health related to NSCLC treatment
Current recommendations for screening of NSCLC

Expert Faculty Presenters


	Sita Bhatt, PharmD, BCOP Clinical Pharmacy Specialist Boston Medical Center Click here for biography

	Andrea E. Ferris President and Chief Executive Officer LUNGevity Click here for biography

	Ryan Haumschild, PharmD, MS, MBA, CPEL Vice President of Pharmacy Emory Healthcare and Winship Cancer Institute Click here for biography

	Michael Kobernick, MD, MS, MS-PopH, CPE Senior Medical Director – Health Plan Business Blue Cross Blue Shield of Michigan Lecturer Jefferson College of Population Health Click here for biography

	Umit Tapan, MD Thoracic Medical Oncologist Boston Medical Center Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Attendees will learn about current treatment paradigms, emerging treatment options, and current screening and biomarker testing guidelines for NSCLC. This symposium will also address how to evaluate the cost-effectiveness of various NSCLC treatment options to inform decision-making and optimize health care resource allocation, all while touching on the impact of social determinants of health on patients with NSCLC.

Educational Objectives
After completing this activity, the participant should be better able to:

Outline current recommendations for screening of NSCLC and characterization of the disease at diagnosis to drive appropriate treatment selection
Evaluate the cost-effectiveness of various treatment options for NSCLC to inform decision-making and optimize healthcare resource allocation
Discuss relevant social determinants of health related to NSCLC treatment

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Credit
Medical Education Resources designates this live activity for a maximum of 1.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.5 contact hours.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-25-062-L01-P
Type of Activity: Knowledge-based

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

*Name of Faculty*	*Reported Financial Relationship*
Sita Bhatt, PharmD, BCOP	Nothing to disclose.
Andrea Ferris	Nothing to disclose.
Ryan Haumschild, PharmD, MS, MBA, CPEL	Nothing to disclose.
Michael Kobernick, MD, MS, MS-PopH, CPE	Nothing to disclose.
Umit Tapan, MD	Coming Soon

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

*Name of Content Managers*	*Reported Financial Relationship*
Impact Education, LLC.	No financial relationships to disclose.
Planners at Medical Education Resources	No financial relationships to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.

Please note: Registration for AMCP 2025 is NOT required to attend this symposium.